A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
← catalyst calendarNCT07115043 · readout in 1,140 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
120estimated
Sites
13
Countries
Australia, Japan, South Korea +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-29 | actual | When the study began enrolling |
| Primary completion | 2029-10-02 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-10-02 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Melanoma
- Non-small Cell Lung Cancer
- Squamous Cell Carcinoma (Skin)
- Renal Cell Carcinoma
- Merkel Cell Carcinoma
- Triple Negative Breast Cancer
- Head and Neck Squamous Cell Carcinoma
- Gastric Cancer/Gastroesophageal Junction Cancer
- High Grade Serous Ovarian Carcinoma
Interventions
- Drug: AZD6750
- Drug: rilvegostomig
Primary outcomes
what the primary-completion date above is the date OFSafety- Part 1A & Part 2A (dose escalation) and Part 2B (dose expansion)
measured Measured from the informed consent until Day 90 post-last dose.
Efficacy- Part 2B only (dose expansion)
measured Measured every 6 weeks for 48 weeks and every 12 weeks thereafter from first dose until disease progression or death in the absence of disease progression(approximately 2 years)
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed